Hu X - Search Results

1

Short-duration versus 1-year adjuvant trastuzumab in early HER2 positive breast cancer: A meta-analysis of randomized controlled trials.

Chen L, Zhou W, Hu X, Yi M, Ye C, Yao G. Chen L, et al. Among authors: hu x. Cancer Treat Rev. 2019 May;75:12-19. doi: 10.1016/j.ctrv.2019.02.003. Epub 2019 Feb 28. Cancer Treat Rev. 2019. PMID: 30856373 Free article. Review.

2

MT1-MMP in breast cancer: induction of VEGF-C correlates with metastasis and poor prognosis.

Yao G, He P, Chen L, Hu X, Gu F, Ye C. Yao G, et al. Among authors: hu x. Cancer Cell Int. 2013 Oct 13;13(1):98. doi: 10.1186/1475-2867-13-98. Cancer Cell Int. 2013. PMID: 24119788 Free PMC article.

3

[Differentially expressed genes and potential signaling pathway in Asian people with breast cancer by preliminary analysis of a large sample of the microarray data].

Chen L, Ye C, Huang Z, Li X, Yao G, Liu M, Hu X, Dong J, Guo Z. Chen L, et al. Among authors: hu x. Nan Fang Yi Ke Da Xue Xue Bao. 2014 Jun;34(6):807-12. Nan Fang Yi Ke Da Xue Xue Bao. 2014. PMID: 24968835 Chinese.

4

The expression of CXCL13 and its relation to unfavorable clinical characteristics in young breast cancer.

Chen L, Huang Z, Yao G, Lyu X, Li J, Hu X, Cai Y, Li W, Li X, Ye C. Chen L, et al. Among authors: hu x. J Transl Med. 2015 May 20;13:168. doi: 10.1186/s12967-015-0521-1. J Transl Med. 2015. PMID: 25990390 Free PMC article.

5

Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials.

Cao L, Yao GY, Liu MF, Chen LJ, Hu XL, Ye CS. Cao L, et al. PLoS One. 2015 Dec 30;10(12):e0145442. doi: 10.1371/journal.pone.0145442. eCollection 2015. PLoS One. 2015. PMID: 26717149 Free PMC article.

6

[Expression pattern of membrane type-1 matrix metalloproteinase in primary breast carcinomas].

Yao G, Chen L, Hu X, Li W, Ye C. Yao G, et al. Among authors: hu x. Nan Fang Yi Ke Da Xue Xue Bao. 2016 Jan;36(1):94-7. Nan Fang Yi Ke Da Xue Xue Bao. 2016. PMID: 26806746 Chinese.

7

[Advances in studies on metabolic syndrome and breast cancer].

Cao L, Yao G, Hu X, Chen L, Ye C. Cao L, et al. Among authors: hu x. Zhonghua Wai Ke Za Zhi. 2015 Dec 1;53(12):966-9. Zhonghua Wai Ke Za Zhi. 2015. PMID: 26850671 Chinese.

8

Gemcitabine and Capecitabine Combination Chemotherapy in Patients with Metastatic Breast Cancer Pretreated with Anthracyclines and/or Taxanes.

Yao G, Cao L, Liu M, Chen L, Hu X, Ye C. Yao G, et al. Among authors: hu x. Chemotherapy. 2016;61(4):171-8. doi: 10.1159/000443366. Epub 2016 Feb 9. Chemotherapy. 2016. PMID: 26854471 Clinical Trial.

9

Erratum to: The expression of CXCL13 and its relation to unfavorable clinical characteristics in young breast cancer.

Chen L, Huang Z, Yao G, Lyu X, Li J, Hu X, Cai Y, Li W, Ye C, Li X. Chen L, et al. Among authors: hu x. J Transl Med. 2016 Nov 15;14(1):318. doi: 10.1186/s12967-016-1069-4. J Transl Med. 2016. PMID: 27846893 Free PMC article. No abstract available.

10

MicroRNA-433 targets AKT3 and inhibits cell proliferation and viability in breast cancer.

Hu X, Wang J, He W, Zhao P, Ye C. Hu X, et al. Oncol Lett. 2018 Mar;15(3):3998-4004. doi: 10.3892/ol.2018.7803. Epub 2018 Jan 16. Oncol Lett. 2018. PMID: 29556282 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

34,927 results

Search Page

Filters